cord blood-derived CD133+ hematopoietic stem cell therapy (EndGenitor)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namecord blood-derived CD133+ hematopoietic stem cell therapy (EndGenitor)

Drug Alias NameCD133+ HSC therapy (Endgenitor)adult stem cell therapy (EndGenitor)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/Indications +[1] N/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesEndGenitor Technologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEndGenitor Technologies Inc

Active IndicationsN/A

Inactive Indications +[1] N/A

Other Information

ATC CodeN/A